Research has shown the ability of triptolide to act as a controller to promote cancer cell-reactive immune responses via the suppression of interferon-γ-induced PD-L1 surface expression leading to down-regulation of the PD-1/PD-L1 pathway (40). The gene discussed is PDCD1; the disease is cancer.